Relmada's RELIANCE III MDD trial failed; RELIANCE I results at risk from similar enrollment issues

RELMADA THERAPEUTICS, INC.

RELIANCE III monotherapy trial failed; placebo group mean change of 23 points at one high-enrolling site; 30% of patients from such sites.
RELIANCE I adjunctive trial results by year-end 2022; 40% of patients from same high-enrolling sites, raising risk of similar failure.
RELIANCE II adjunctive trial results delayed to 2023; protocol changes being implemented.
Q3 2022 net loss $39.4M ($1.31/diluted) vs $42.6M ($2.44) prior year; cash $184.2M.
Company states it has financial flexibility to continue advancing REL-1017.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RELMADA THERAPEUTICS, INC. reported the nine months ended September 30, 2022 results: net income $119.1 million, EPS $4.04 per share.

Period: the nine months ended September 30, 2022
Net income: $119.1 million
EPS: $4.04 per share
Result: preliminary results

Exact text from the filing

Net loss for the nine months ended September 30, 2022 and 2021 was $119.1 million and $91.4 million, respectively. The Company had a net loss of $4.04 and $5.36 per share for the nine months ended September 30, 2022 and 2021, respectively.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RELMADA THERAPEUTICS, INC. reported the three months ended September 30, 2022 results: net income $39.4 million, EPS $1.31 per diluted share.

Period: the three months ended September 30, 2022
Net income: $39.4 million
EPS: $1.31 per diluted share
Result: preliminary results

Exact text from the filing

The net loss for the three months ended September 30, 2022, was $39.4 million, or $1.31 per diluted share, compared with a net loss of $42.6 million, or $2.44 per diluted share, for the three months ended September 30, 2021.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-22-071296

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.